These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 38967596)

  • 1. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.
    Zhang R; Yan Z; Zhong H; Luo R; Liu W; Xiong S; Liu Q; Liu M
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials.
    Wu J; Chen X; Qian J; Li G
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102397. PubMed ID: 38879003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutritional Interventions, Probiotics, Synbiotics and Fecal Microbiota Transplantation in Steatotic Liver Disease : Pediatric Fatty Liver and Probiotics.
    Nicastro E; D'Antiga L
    Adv Exp Med Biol; 2024; 1449():113-133. PubMed ID: 39060734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.
    Vallianou NG; Kounatidis D; Psallida S; Vythoulkas-Biotis N; Adamou A; Zachariadou T; Kargioti S; Karampela I; Dalamaga M
    Metabolites; 2024 Jun; 14(7):. PubMed ID: 39057689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.
    Liang Y; Cui L; Gao J; Zhu M; Zhang Y; Zhang HL
    Mol Neurobiol; 2021 Aug; 58(8):3745-3758. PubMed ID: 33825149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic Steatosis Can Be Partly Generated by the Gut Microbiota-Mitochondria Axis via 2-Oleoyl Glycerol and Reversed by a Combination of Soy Protein, Chia Oil, Curcumin and Nopal.
    Sánchez-Tapia M; Tobón-Cornejo S; Noriega LG; Vázquez-Manjarrez N; Coutiño-Hernández D; Granados-Portillo O; Román-Calleja BM; Ruíz-Margáin A; Macías-Rodríguez RU; Tovar AR; Torres N
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological Study on the Interaction between the
    Sato S; Iino C; Sasada T; Soma G; Furusawa K; Yoshida K; Sawada K; Mikami T; Nakaji S; Sakuraba H; Fukuda S
    Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review.
    Martin-Grau M; Monleón D
    Curr Issues Mol Biol; 2024 Jun; 46(7):6377-6389. PubMed ID: 39057023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Ha S; Wong VW; Zhang X; Yu J
    Gut; 2024 Jun; ():. PubMed ID: 38950910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiomes in physiology: insights into 21st-century global medical challenges.
    Shehata E; Parker A; Suzuki T; Swann JR; Suez J; Kroon PA; Day-Walsh P
    Exp Physiol; 2022 Apr; 107(4):257-264. PubMed ID: 35081663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
    Wu J; Yang K; Fan H; Wei M; Xiong Q
    Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.